Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch Health Companies Inc. (BHC) CEO Joe Papa Presents at 2022 Barclays Global Healthcare Conference (Transcript)

Cowen

Bausch Health Companies Inc. (BHC) CEO Joe Papa Presents at Cowen 42nd Annual Healthcare Conference (Transcript)

With another rough day in the markets unfolding, we want to put a small amount of money to work in quality companies.

Investing Club: We're adding to a health stock in Monday's market slide — here's what else we're watching

Students Impacted by Dermatologic Conditions Are Encouraged to Apply Through May 31, 2022 LAVAL, Quebec, March 2, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the opening of the application process for its 2022 Aspire Higher Scholarship program. The program, which was launched in 2013, will award nine students who have been treated for a dermatologic condition with a scholarship of up to $10,000 in support of their academic goals.

Ortho Dermatologics Now Accepting Applications for 2022 Aspire Higher Scholarship Program

MINNEAPOLIS and BRIDGEWATER, N.J., March 1, 2022 /PRNewswire/ -- The Colon Cancer Coalition, a national nonprofit organization focusing on grass roots efforts to increase screening and awareness for colorectal cancer, and Salix Pharmaceuticals ("Salix"), the gastroenterology (GI) business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, are joining for the second consecutive year to raise awareness of the importance of colorectal cancer screenings.

Salix and Colon Cancer Coalition Join Forces for 'Faces of Blue' Story Series to Raise Awareness of Colorectal Cancer Screenings

Bausch (BHC) beats on earnings but misses on sales in the fourth quarter. The outlook for 2022 is disappointing.

Bausch's (BHC) Q4 Earnings Beat Estimates, Revenues Miss

LAVAL, QC, Feb. 24, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that Sam Eldessouky, executive vice president and chief financial officer; William Woodfield, senior vice president and treasurer; and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the J.P.

Bausch Health Announces Participation At The J.P. Morgan Global High Yield & Leveraged Finance Conference

Bausch Health Companies Inc. (BHC) CEO Joseph Papa on Q4 2021 Results - Earnings Call Transcript

The upcoming Bausch + Lomb and Solta Medical IPOs are key to realizing upside earnings power locked away in the bigger company.

Investing Club: We're looking past Bausch's mixed quarter to the greater value a breakup brings

Disney

When you see the market higher like it was earlier Wednesday on no news, sometimes the best action can be to wait to see if it holds.

Investing Club: We're using Wednesday's market reversal to buy more of two stocks on the dip

Bausch (BHC) delivered earnings and revenue surprises of 17.59% and 0.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Beats Q4 Earnings Estimates

Bausch Health Companies Inc (NYSE: BHC) has reported Q4 revenues of $2.19 billion, down 1% Y/Y, missing the consensus of $2.80 billion. Excluding the impact of foreign exchange, divestitures & discontinuations, revenue was flat organically.

Bausch Health Companies Q4 Sales, FY22 Outlook Lag Wall Street View

Shares of Bausch Health Companies Inc. BHC, -1.34% rallied 2.3% in premarket trading Wednesday, after the health care products company swung to fourth-quarter net income, while revenue and the full-year outlook fell shy of expectations. The company swung to net income of $69 million, or 19 cents a share, from a loss of $153 million, or 43 cents a share, in the year-ago period.

Bausch Health swings to a profit, while revenue and full-year outlook misses expectations

LAVAL, Quebec, Feb. 23, 2022 /PRNewswire/ -- Fourth-Quarter 2021 Financial Results Revenues of $2.196 Billion GAAP Net Income of $69 Million Adjusted EBITDA (non-GAAP)1 of $909 Million GAAP Cash Generated from Operations of $24 Million Full-Year 2021 Financial Results Revenues of $8.434 Billion GAAP Net Loss of $948 Million Adjusted EBITDA (non-GAAP)1 of $3.472 Billion GAAP Cash Generated from Operations of $1.426 Billion Full-Year 2021 Reported Revenue Grew 5% Compared to the Full Year of 2020 Bausch Health Filed Public Registration Statements for Bausch + Lomb and Solta and Is Prepared to Launch Both IPOs 2 ,3 Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company" or "we") today announced its fourth-quarter and full-year 2021 financial results. "In 2021, our reported revenues grew by five percent as several of our key products gained market share, and we delivered on our near-term R&D catalysts with four new product launches," said Joseph C.

Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2021 Results And Provides 2022 Guidance

BioMarin Pharmaceutical

Clovis Oncology

Global Blood Therapeutics

Theravance Biopharma

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More

LAVAL, QC, Feb. 22, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its oral health care business, OraPharma, today announced the U.S. launch of the OraFit™ custom clear aligner system, which is indicated for correcting malocclusion, which is also known as crooked or misaligned permanent teeth. The new OraFit™ aligner system uses high-performance materials in a three-layer design that offers dental professionals and their patients the latest in clear aligner technology and addresses the increased demand for improved aesthetics, more comfortable aligners and overall long-term oral health.1 "Malocclusion is one of the most common dental problems, and it impacts approximately two out of three people in the United States 3," said Joseph C.

OraPharma Launches OraFit™ Custom Clear Dental Aligner System

An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.

What's in the Cards for Bausch Health (BHC) Q4 Earnings?

Salix to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC, Feb. 15, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) "Bausch Health" and its gastroenterology business, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today announced the opening of the 2022 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to $10,000 as they work to pursue their higher education goals.

Salix Announces 2022 Gastrointestinal Health Scholars Program

Solta Medical has filed for a U.S. IPO as part of a separation process from its parent firm, Bausch Health Companies. The firm designs and sells medical aesthetic devices in 50 countries worldwide.

Solta Medical Begins Separation From Bausch Parent Via U.S. IPO

As Club members know, we're looking to these IPOs as a means of unlocking value by separating the three core operating business.

CNBC Investing Club: Bausch drops details on one of its planned IPOs that will unlock value

LAVAL, QC and VAUGHAN, ON, Feb. 8, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that its wholly owned subsidiary, Solta Medical Corporation ("Solta"), has publicly filed a registration statement on Form S-1 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering ("IPO") of Solta's common shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined.

Solta Medical Corporation Files Registration Statement for Proposed Initial Public Offering

LAVAL, QC, Feb. 3, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its fourth-quarter and full-year 2021 financial results on Wednesday, Feb. 23, 2022. Bausch Health will host a conference call and live web cast at 8:00 a.m.

Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2021 Financial Results on February 23

Social Media Initiative Includes Donation to Prevent Blindness' Sight-Saving Fund BRIDGEWATER, N.J. and CHICAGO, Feb. 1, 2022 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies, Inc., and Prevent Blindness, the nation's oldest volunteer eye health non-profit organization, today announced they are joining together for the seventh consecutive year during AMD Awareness Month to share education and raise greater awareness of Age-Related Macular Degeneration (AMD), a leading cause of vision loss in adults 50 years and older that affects approximately 16 million people in America1.

BAUSCH + LOMB AND PREVENT BLINDNESS LAUNCH ANNUAL AMD AWARENESS MONTH CAMPAIGN TO EDUCATE PATIENTS

In the latest trading session, Bausch Health (BHC) closed at $24.57, marking a +1.78% move from the previous day.

Bausch Health (BHC) Gains But Lags Market: What You Should Know

Bausch Health is unlocking value by spinning off into 3 separate companies. The partial Bausch and Lomb & Solta spinoff proceeds will be used to pay down debt.

News for Bausch Health Companies Inc Stock (BHC)